MedinCell publishes its financial results for the first semester of 2022-2023 (April – September 2022)

Revenue: €7.7 million (+89% compared to the first half of the previous year)
Operating expenses: €19.4 million (+27% compared to the first half of the previous year)
Cash consumption from operations: €10 million
Available cash: €11.7 million in cash and cash equivalent + €2.5 million in non-risky current financial assets in September 30, 2022
Post-closing: expected cash inflows of more than €29 million by the end of the first semester 2023 and revision of the investment plan